Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) traded up 6.5% during trading on Thursday . The company traded as high as $17.24 and last traded at $16.94, with a volume of 288,905 shares trading hands. The stock had previously closed at $15.90.

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Thursday, May 26th. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Wednesday, July 13th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 1st. Lake Street Capital assumed coverage on Flexion Therapeutics in a research note on Thursday. They set a “buy” rating and a $38.00 price target for the company. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $33.17.

The firm has a 50-day moving average price of $15.06 and a 200 day moving average price of $12.67. The firm’s market cap is $357.63 million.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.17. Analysts forecast that Flexion Therapeutics Inc. will post ($2.84) earnings per share for the current fiscal year.

In other news, Director Samuel D. Colella bought 6,778 shares of the company’s stock in a transaction dated Monday, June 20th. The stock was bought at an average cost of $13.84 per share, for a total transaction of $93,807.52. Following the completion of the acquisition, the director now owns 3,435 shares in the company, valued at approximately $47,540.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Samuel D. Colella bought 714,285 shares of the company’s stock in a transaction dated Wednesday, June 8th. The shares were purchased at an average price of $14.00 per share, with a total value of $9,999,990.00. The disclosure for this purchase can be found here.

Other hedge funds have recently bought and sold shares of the company. Jennison Associates LLC raised its stake in Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares in the last quarter. Jennison Associates raised its stake in Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares in the last quarter. Schroder Investment Management Group raised its stake in Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares in the last quarter.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.